Rani Therapeutics Holdings, Inc.

NGM: RANI

Live Quote

📈 ZcoreAI Score

Our AI model analyzes Rani Therapeutics Holdings, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.

Get RANI Z-Score →

About Rani Therapeutics Holdings, Inc.

Healthcare Biotechnology

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

📊 Fundamental Analysis

Rani Therapeutics Holdings, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.

The company recently reported 42.1% revenue growth, which is well above average for the Healthcare sector.

Return on Equity (ROE) is -182.0%, which indicates that capital utilization is currently under pressure.

At a current price of $0.74, RANI currently trades near the bottom of its 52-week range (10%), indicating potential value or weakness (Range: $0.39 - $3.87).

🏥 Financial Health

🔴 Profit Margin Weak

✅ Debt/Equity Excellent

✅ Revenue Growth Excellent

🔴 Return on Equity Weak

✅ Beta (Risk) Low Volatility

Key Financials

Market Cap

$73.79M

Trailing P/E

Forward P/E

-3.61

Beta (5Y)

0.66

52W High

$3.87

52W Low

$0.39

Avg Volume

1.12M

Day High

Day Low

Get RANI Z-Score on Dashboard 🚀